On January 1, 2016, the appointment of Frank Luppino as Anika Therapeutics Inc.'s Chief Operating Officer has ended, as planned. Moving forward, Mr. Luppino will continue to serve as a consultant to Anika Therapeutics Inc. on an as-needed basis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.66 USD | +1.18% |
|
+1.30% | +13.24% |
07-01 | Anika Therapeutics, Inc.(NasdaqGS:ANIK) added to Russell 3000 Growth Index | CI |
07-01 | Anika Therapeutics, Inc.(NasdaqGS:ANIK) added to Russell Microcap Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.24% | 381M | |
+4.57% | 97.7B | |
+5.66% | 41.43B | |
-12.80% | 32.85B | |
+80.99% | 29.33B | |
-15.53% | 15.47B | |
-8.70% | 12.89B | |
-12.22% | 11.51B | |
+183.25% | 10.74B | |
+3.60% | 8.97B |
- Stock Market
- Equities
- ANIK Stock
- News Anika Therapeutics, Inc.
- Anika Therapeutics Inc. Announces Resignation of Frank Luppino as Chief Operating Officer